Advances in endothelial progenitor cells/toll like receptors in neovascular age-related macular degeneration
10.3980/j.issn.1672-5123.2025.4.10
- VernacularTitle:EPCs/TLRs在新生血管性年龄相关性黄斑变性中的研究进展
- Author:
Changqin WANG
1
;
Jianfeng LI
1
;
Yang LYU
1
Author Information
1. Ophthalmic Center, the 940 Hospital of Joint Service Support Forces of the Chinese People's Liberation Army, Lanzhou 730000, Gansu Province, China; The First Clinical Medical School, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
- Publication Type:Journal Article
- Keywords:
toll-like receptors(TLRs);
endothelial progenitor cells(EPCs);
neovascular age-related macular degeneration;
SDF-1/CXCR4
- From:
International Eye Science
2025;25(4):577-582
- CountryChina
- Language:Chinese
-
Abstract:
Neovascular age-related macular degeneration(ARMD)is a condition where various causes induce the formation of choroidal neovascularization(CNV)in the macula, leading to macular hemorrhage, accumulation of fluid, and development of fibrosis, resulting in a large, dark spot in the center of the visual field, causing severe central vision loss in over 90% of patients. Endothelial progenitor cells(EPCs)are a heterogeneous group of cells that play a crucial role in neovascularization. Under pathological stimulation, EPCs are mobilized into the systemic circulation, migrate toward the avascular zone, and promote the restoration of blood vessels and endothelialization in the damaged area. Toll-like receptors(TLRs)are pattern recognition receptors and type Ⅰ transmembrane proteins that are mainly expressed in monocytes, dendritic cells, and other immune cells, recognizing the surface of pathogens and transmitting signals to cells, participating in the innate immune response and adaptive immune response. Studies have shown that most TLRs are involved in the development of neovascularization, and EPCs can express TLRs. Therefore, exploring the role of EPCs/TLRs in the pathogenesis of ARMD can help us understand the disease and may provide new insights for targeted therapy in the future.
